Anstelai will invest heavily in general car / tcr-t cell therapy

On January 14, Japanese pharmaceutical company astralas pharma and British company adaptive therapeutics reached a cooperation agreement worth up to 897.5 million US dollars to jointly develop and commercialize stem cell-derived allogeneic T-cell therapy (car-t and tcr-t) It is worth mentioning that this is the second major layout of astralas in the field of T-cell therapy in the near future Just half a month ago, astralas completed its second round of acquisition in December 2019, and won car-t therapy company xyphos with us $665 million This time, it also spent a lot of money to reach a cooperation deal, which can be seen from its emphasis on the field of T-cell therapy The other partner, adaptimmune, just reported its spear on January 13 at the 38th J.P Morgan Healthcare Conference The initial mitigation data of T-cell technology in liver cancer, melanoma, gastroesophageal junction cancer and head and neck cancer show the potential of the platform to span multiple targets and treat a series of solid tumors, and the share price of the company soared 200% on that day This cooperation can be described as a strong alliance! The cooperation agreement covers the joint development and commercialization of up to three kinds of T-cell therapy, and utilizes the leading technology platform of both sides, the universal donor cell platform of astralas and the allogeneic T-cell platform derived from stem cells of adaptimmune Under the agreement, astralas will pay to adaptimmune advance payments, research funding, development and commercial milestones, as well as a share of the net sales of the co commercialized products Astralas funds research on each candidate product until the first phase of testing is completed After completing the first phase test of each candidate product, astralas and adaptimmune will choose whether to further jointly develop and commercialize the candidate product, or let one party independently continue to develop the candidate product through milestone and franchise license, and both parties agree to allow either party to opt out Both companies will have the exclusive right to jointly develop and commercialize the candidate products in the field of T-cell therapy If a candidate product is developed by only one company, the relevant license rights will only belong to the continuing party Specifically, adaptimmune may receive up to $897.5 million, and astralas may receive $552.5 million Adaptimmune will receive US $50 million in advance, up to US $73.75 million in development milestone payments per product for products jointly developed and commercialized by the two companies, and up to US $7.5 million in research funding per year for adaptimmune Both parties can charge a commission of 10% to 15% from the net sales For any product developed unilaterally by one company, another company will receive milestone payments of up to $147.5 million per product and sales milestone payments of up to $110 million Astralas will also have the right to select two targets and independently develop candidate products for allogeneic cell therapy Astralas will have the exclusive right to develop and commercialize these products, subject to the necessary licensing and payment of milestone payments and royalties Astralas and adaptimmune jointly develop and commercialize any T-cell therapy, and they will share equally the cost of such co development and commercialization, as well as the profit of CO commercialization Further details on co development and commercialization will be set out in the commercialization agreement for specific products In 2018, astralas acquired its universal donor cell technology based on gene editing through the acquisition of universal cells, which can create cell therapy without considering HLA matching, and is expected to overcome the treatment risk brought by rejection; before that, astralas also integrated its own pluripotent stem cell (IPSC) differentiation technology with it, aiming to bring cell therapy with lower immune rejection Since 2015, adaptimmune has been cooperating with universal cells in the development of IPSC cell lines for gene editing Adaptimmune has the right to develop and commercialize the T cell treatment products produced by this patented technology The cooperation also uses the target recognition and verification capabilities of adaptimmune company to generate target specific T cell receptors (TCRs), chimeric antigen receptors (cars) and HLA independent TCRs The two sides will reach an agreement on three targets and jointly develop T-cell treatment candidate products for these targets, and these targets will not be included in the target specific T-cell products developed by adaptimmune company in preclinical, clinical trials or for other partners "We are very pleased to establish this important common development partnership with Astellas, which is based on the existing cooperation focusing on IPSC cell gene editing and has greatly expanded this cooperation." "This new collaboration may include car-t and TCR T cells, including our new HLA independent TCR (" hit ") platform," said Helen tayton Martin, chief business officer and co-founder of adaptimmune The collaboration brings together highly complementary skills and expertise between the two companies and will accelerate the development of new, off the shelf T-cell therapy products for cancer patients " In addition, for adaptimmune, this cooperation with astralas may come at the right time Because last year, a series of changes took place in the executives of adaptimmune, while the company's share price has been underperforming The preliminary data of pear T cells reported at the 38th JPMorgan medical and health conference made its share price rise significantly Although the product needs more patient data and persistent data support, it at least initially demonstrates the potential of the platform to span multiple targets and treat a series of solid tumors "Immunooncology has always been one of the strategic areas that astralas focuses on and is committed to using a new model / technology to develop new treatments for cancer patients." Naoki, executive vice president, chief strategy officer, chief financial officer, astralas "In addition to NK cells, T cells are an important part of tumor immunotherapy, and we look forward to this agreement with adaptimmune that will enable us to create new stem cell derived allogeneic T cell therapies for a variety of cancers, including solid tumors, in the future," Okamura said And yesterday, through its Massachusetts subsidiary, the astralas Institute of regenerative medicine (airm), it entered into a license agreement with allele to expand its access to cell therapy programs using allele's induced pluripotent stem cell (IPSC) technology Allele company has been developing the technology of reprogramming somatic cells into IPSC as its core strength in the past 10 years It has obtained a number of national patents and developed the first commercial cGMP system In recent years, a series of layout of astralas in the field of cell therapy has highlighted its emphasis on this treatment strategy, and also reflected its market potential We hope that the cooperation between the two sides can bring more convenient and effective treatment programs for more patients.